Ivy Leaf: Safety in Children and Allergy

Ivy leaf cough syrups are marketed heavily for children, and their short-term tolerability record is good. They are also the subject of a firm regulatory limit: the European Union contraindicates them in children under two years of age. And the plant they come from has hazards of its own — a sap that causes blistering rashes, and berries and leaves that are poisonous to eat.

This page sets out what is known about the safety of ivy leaf extract and of the ivy plant, separately, because they are different exposures. It reports findings and regulatory statements; questions about giving any medicine to a particular child are for a clinician or pharmacist.

Table of Contents

  1. Two Different Exposures
  2. The Under-Two Contraindication
  3. Ages Two to Four
  4. How Well the Extract Is Tolerated
  5. Allergic Reactions to the Extract
  6. Pregnancy, Stomach Problems and Alcohol
  7. Overdose and Accidental Swallowing
  8. Occupational Asthma
  9. Gardener's Rash: Contact Dermatitis From Fresh Ivy
  10. Eating the Plant: Berries and Leaves
  11. When a Cough Is More Than a Cough
  12. Key Research Papers
  13. Connections

Two Different Exposures

Ivy leaf medicines contain an extract made from dried leaves, standardised by its content of the saponin hederacoside C and taken in measured doses for a week or so. The safety data below come from people taking those products.

The living plant is another matter. Its sap contains polyacetylene compounds, chiefly falcarinol, that sensitise skin; its berries and leaves contain saponins and polyacetylenes in amounts that nobody measures before a child puts them in their mouth. The plant's hazards are covered in the later sections. A good safety record for the extract says nothing about the plant, and the plant's toxicity says little about the extract.

The Under-Two Contraindication

The European Union herbal monograph on ivy leaf, adopted by the European Medicines Agency's herbal committee in November 2017, lists as a contraindication: "Children under 2 years of age because of the general risk of aggravation of respiratory symptoms through secretolytic drugs" (EMA: Hederae helicis folium).

What "secretolytic" means and why it matters for infants

A secretolytic medicine loosens or increases airway mucus so it can be coughed up. Older children and adults can usually clear that extra mucus by coughing. Infants have narrow airways and a weak cough, so loosened secretions can pool and make breathing harder rather than easier. The wording "general risk" signals that this is a concern about the whole class of mucus-loosening medicines in infants, not a specific set of harms reported for ivy.

A conflicting review

A 2023 review of one ivy extract, coded EA 575, reported that it was "generally well tolerated, with a low incidence of adverse events in children of all ages, including those aged <1 year" (Seifert 2023). The 2026 evidence-map review nevertheless reports the EU monograph's position plainly: it "contraindicates use below two years" (Pawłowska 2026). Both statements are accurate: low reported side-effect rates in observational studies and a regulatory contraindication based on a class risk can coexist. The regulatory position is the one that applies to products authorised in the European Union.

Ages Two to Four

For the next age band, the monograph does not contraindicate use but states under special warnings: "Persistent or recurrent cough in children between 2-4 years of age requires medical diagnosis before treatment."

The reason is diagnostic. In toddlers, a cough that lingers or keeps coming back can be a sign of asthma, an inhaled foreign object, whooping cough or another condition that a cough syrup does not address. The monograph also lists separate, lower doses for children aged 2 to 5, with a lower maximum for products that contain alcohol.

A 2025 review of herbal medicines for children's respiratory infections found that of 45 reports, only nine were double-blind and placebo-controlled, and that for most herbal products, ivy included, further research is needed (Kamin 2025). The safety record in young children therefore rests more on observational data than on controlled trials.

How Well the Extract Is Tolerated

Across very different study designs, short-term tolerability is consistently reported as good.

The 2026 review names gastrointestinal and hypersensitivity reactions as the principal recognised adverse effects (Pawłowska 2026). The EU monograph lists gastrointestinal reactions — nausea, vomiting, diarrhoea — with frequency not known.

Two limits apply to all of this: the studies were short, and none followed people taking ivy for months. And a 2.1% adverse-event rate in an open study, where side effects depend on patients and doctors noticing and reporting them, is likely an undercount compared with a blinded trial's systematic questioning — which may be why the blinded Korean trial found a rate around five times higher.

Allergic Reactions to the Extract

The EU monograph lists allergic reactions — hives (urticaria), skin rash, breathlessness (dyspnoea) and anaphylactic reaction — as reported, frequency not known. It contraindicates use in people with hypersensitivity to the active substance or to other plants of the Araliaceae family, the family that includes ivy and ginseng.

The rarity of these reactions cannot be pinned down from the published studies, which are too small or too loosely monitored to estimate the frequency of uncommon events. What is established is that they occur and that the most serious form, anaphylaxis, is on the regulator's list.

Pregnancy, Stomach Problems and Alcohol

Overdose and Accidental Swallowing

The monograph states that overdose "can provoke nausea, vomiting, diarrhoea and agitation," and records one case: a 4-year-old child who developed aggressiveness and diarrhoea after accidentally taking an ivy extract corresponding to 1.8 g of dried leaf.

Occupational Asthma

Ivy can sensitise the airways as well as the skin. A 2008 report in the journal Allergy describes occupational asthma caused by ivy (Hannu 2008) — asthma that developed from exposure in the course of work. Reports like this concern people with heavy, repeated exposure to the plant, such as in horticulture or plant handling, rather than people taking a cough medicine.

Gardener's Rash: Contact Dermatitis From Fresh Ivy

The best-known hazard of ivy has nothing to do with cough medicine. Contact with the fresh plant causes both irritant and allergic contact dermatitis. DermNet, the New Zealand dermatology reference, describes the typical setting as pulling ivy off walls and trees, identifies falcarinol and didehydrofalcarinol as the main allergens, and describes an itchy rash with small blisters on exposed skin — hands, arms, face and neck — that can look like poison ivy (DermNet: English ivy).

The reaction comes from the sap released when stems and leaves are cut or torn, which is why it clusters in gardeners, landscapers and people clearing overgrown buildings. The North Carolina State Extension plant database describes contact with ivy cell sap as causing "severe skin irritation with redness, itching, and blisters" (NC State Extension: Hedera helix).

Despite the similar appearance, this is not poison ivy. Poison ivy is an unrelated plant whose rash is caused by urushiol.

Eating the Plant: Berries and Leaves

Ivy's black berries ripen in late winter and early spring, when few other fruits are around, which makes them noticeable to small children. The North Carolina State Extension database lists the toxic principles as triterpenoid saponins and polyacetylene compounds and rates poison severity as medium. It reports that eating the berries causes burning in the throat, and that eating the leaves can cause vomiting, abdominal pain, fever and rash and, in larger amounts, delirium, stupor, hallucinations and convulsions (NC State Extension: Hedera helix).

The saponins that are studied in measured micromolar amounts in the laboratory are toxic to cells at higher concentrations; a 2019 study proposed that alpha-hederin forms pores in cholesterol-rich cell membranes, a mechanism the authors link to its toxicity to cells (Jeong 2019). Eating raw plant material delivers these compounds in amounts that are neither standardised nor small. Suspected poisoning from any plant is a matter for a poison control centre or emergency service.

When a Cough Is More Than a Cough

The EU monograph states that "when dyspnoea, fever or purulent sputum occurs, a doctor or a pharmacist should be consulted," and that if symptoms persist longer than one week during use, a doctor or pharmacist is to be consulted. Those three signs — breathlessness, fever and pus-like (yellow-green, thick) sputum — can indicate pneumonia or another infection that needs assessment.

In children, conditions that start with a cough and can need urgent care include croup (a barking cough with noisy breathing), bronchiolitis in infants, asthma attacks and whooping cough. The site's pages on croup, bronchiolitis and pneumonia describe their warning signs. The research on ivy leaf concerns ordinary acute cough and bronchitis, not these conditions.

Key Research Papers

  1. Pawłowska AM. From Traditional Remedy to Evidence-Based Phytotherapeutic Agent: Hedera helix L. in Respiratory Medicine. Plants (Basel, Switzerland). 2026;15(17). PubMed PMID: 42739377
  2. Seifert G, Upstone L, Watling CP, et al. Ivy leaf dry extract EA 575 for the treatment of acute and chronic cough in pediatric patients: review and expert survey. Current medical research and opinion. 2023;39(10):1407-1417. PubMed PMID: 37731370
  3. Fazio S, Pouso J, Dolinsky D, et al. Tolerance, safety and efficacy of Hedera helix extract in inflammatory bronchial diseases under clinical practice conditions: a prospective, open, multicentre postmarketing study in 9657 patients. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2009;16(1):17-24. PubMed PMID: 16860549
  4. Sierocinski E, Holzinger F, Chenot JF. Ivy leaf (Hedera helix) for acute upper respiratory tract infections: an updated systematic review. European journal of clinical pharmacology. 2021;77(8):1113-1122. PubMed PMID: 33523253
  5. Cho YJ, Yoon HJ, Lim DH, et al. Randomized, Double-Blind, Multicenter, Phase 3 Study of AG NPP709 Compared With Ivy Leaf Extract in Patients With Acute or Chronic Respiratory Symptoms. Journal of Korean medical science. 2026;41(9):e97. PubMed PMID: 41807028
  6. Zeil S, Schwanebeck U, Vogelberg C. Tolerance and effect of an add-on treatment with a cough medicine containing ivy leaves dry extract on lung function in children with bronchial asthma. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2014;21(10):1216-20. PubMed PMID: 24916707
  7. Hofmann D, Hecker M, Völp A. Efficacy of dry extract of ivy leaves in children with bronchial asthma--a review of randomized controlled trials. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2003;10(2-3):213-20. PubMed PMID: 12725580
  8. Kamin W, Seifert G, Zwiauer K, et al. Phytotherapy for acute respiratory tract infections in children: a systematically conducted, comprehensive review. Frontiers in pediatrics. 2025;13:1423250. PubMed PMID: 40376625
  9. Hannu T, Kauppi P, Tuppurainen M, et al. Occupational asthma to ivy (Hedera helix). Allergy. 2008;63(4):482-3. PubMed PMID: 18315739
  10. Jeong KB, Luo K, Lee H, et al. Alpha-Hederin Nanopore for Single Nucleotide Discrimination. ACS nano. 2019;13(2):1719-1727. PubMed PMID: 30657663

PubMed Topic Searches

  1. PubMed: Hedera helix contact dermatitis falcarinol
  2. PubMed: ivy leaf extract adverse events children
  3. PubMed: Hedera helix poisoning

Back to Table of Contents

Connections

Back to Table of Contents